1. Home
  2. GMED vs MDGL Comparison

GMED vs MDGL Comparison

Compare GMED & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GMED
  • MDGL
  • Stock Information
  • Founded
  • GMED 2003
  • MDGL 2011
  • Country
  • GMED United States
  • MDGL United States
  • Employees
  • GMED N/A
  • MDGL N/A
  • Industry
  • GMED Medical/Dental Instruments
  • MDGL Biotechnology: Pharmaceutical Preparations
  • Sector
  • GMED Health Care
  • MDGL Health Care
  • Exchange
  • GMED Nasdaq
  • MDGL Nasdaq
  • Market Cap
  • GMED 7.2B
  • MDGL 6.1B
  • IPO Year
  • GMED 2012
  • MDGL N/A
  • Fundamental
  • Price
  • GMED $56.76
  • MDGL $432.79
  • Analyst Decision
  • GMED Buy
  • MDGL Strong Buy
  • Analyst Count
  • GMED 13
  • MDGL 10
  • Target Price
  • GMED $87.30
  • MDGL $474.67
  • AVG Volume (30 Days)
  • GMED 962.0K
  • MDGL 329.8K
  • Earning Date
  • GMED 11-04-2025
  • MDGL 10-30-2025
  • Dividend Yield
  • GMED N/A
  • MDGL N/A
  • EPS Growth
  • GMED 745.36
  • MDGL N/A
  • EPS
  • GMED 2.57
  • MDGL N/A
  • Revenue
  • GMED $2,626,461,000.00
  • MDGL $515,547,000.00
  • Revenue This Year
  • GMED $15.55
  • MDGL $394.12
  • Revenue Next Year
  • GMED $7.97
  • MDGL $57.74
  • P/E Ratio
  • GMED $21.83
  • MDGL N/A
  • Revenue Growth
  • GMED 17.43
  • MDGL 3421.98
  • 52 Week Low
  • GMED $51.79
  • MDGL $200.63
  • 52 Week High
  • GMED $94.93
  • MDGL $457.16
  • Technical
  • Relative Strength Index (RSI)
  • GMED 41.13
  • MDGL 60.34
  • Support Level
  • GMED $56.07
  • MDGL $415.53
  • Resistance Level
  • GMED $58.35
  • MDGL $440.90
  • Average True Range (ATR)
  • GMED 1.29
  • MDGL 14.03
  • MACD
  • GMED -0.54
  • MDGL -5.22
  • Stochastic Oscillator
  • GMED 12.55
  • MDGL 41.68

About GMED Globus Medical Inc.

Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. The firm's products are organized into two categories: musculoskeletal solutions, which include medical devices and instruments used mostly for spinal and orthopedic procedures, and enabling technologies, which include computer systems developed for enhancing surgical capabilities. The vast majority of the company's revenue is generated from musculoskeletal solutions products, and more than half of the revenue is earned in the United States. It also has its presence internationally.

About MDGL Madrigal Pharmaceuticals Inc.

Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.

Share on Social Networks: